| |
|
|
|
|
|
|
|||
|
Prepublished online as a Blood First Edition Paper on January 2, 2003; DOI 10.1182/blood-2002-09-2817.
IMMUNOBIOLOGY
From the Department of Internal Medicine II, Chiba
University School of Medicine, Chiba, Japan.
Interleukin-25 (IL-25) is a recently described T helper 2 (TH2) cell-derived cytokine that belongs to the
IL-17 family and induces the production of IL-4, IL-5, and IL-13 from
an unidentified non-T-cell population. Here, we show that mast cells
are also potent IL-25-producing cells. When bone marrow-derived mast
cells were stimulated by immunoglobulin E
cross-linking, IL-25 mRNA was induced within 30 minutes in a
calcineurin-dependent manner, and the levels of IL-25 mRNA were
comparable with those of activated TH2 cells. Production of
IL-25 by mast cells was also detected at protein levels by
immunoblotting. These results suggest that mast cells may enhance
TH2-type immune response by producing IL-25.
(Blood. 2003;101:3594-3596) Recently, cytokines homologous to interleukin
(IL)-17 have been identified by database searching. There have
been 5 new family members identified, namely IL-17B, IL-17C, IL-17D,
IL-17E/IL-25, and IL-17F, which possess 20% to 30% homology to
IL-17.1,2 Among IL-17 family cytokines, it has been shown
that the in vivo and in vitro biologic activities of IL-25 are markedly
different from those described for IL-17 and other IL-17 family
cytokines.2-7 The expression of IL-25 results in the
expansion of eosinophils through the production of IL-5 from an
unidentified non-T-cell population,2-4 whereas other
IL-17 family cytokines induce the expansion of
neutrophils.5-7 In addition, IL-25 induces
elevated gene expression of IL-4 and IL-13 in multiple tissues and the resultant T helper 2 (TH2)-type immune responses
(increased serum immunoglobulin E [IgE] levels and pathologic
changes in the lungs and digestive tract with eosinophilic infiltrates,
increased mucus production, and epithelial cell
hyperplasia,2-4), indicating that IL-25 is capable of
amplifying allergic inflammation.
Although it has been shown that IL-25 mRNA is exclusively
expressed in polarized TH2 cells,4
quantitative reverse transcriptase-polymerase chain reaction
(RT-PCR) analysis shows that IL-25 mRNA is detected in multiple
tissues, including colon, uterus, stomach, small intestine, kidney, and
lung,2-4 suggesting that, in addition to TH2
cells, other cell types may produce IL-25. We show here that primary bone marrow-derived mast cells (BMMCs) produce IL-25 upon IgE cross-linking, suggesting that, in addition to TH2 cells,
mast cells are potent IL-25 producers and mast cell-derived IL-25 may be involved in the augmentation of TH2-type immune response.
Cell culture
RT-PCR assay
Taqman PCR analysis Expression of IL-25 mRNA was determined by real-time Taqman PCR using standard protocol on ABI PRISM 7000 instrument (Applied Biosystems, Foster City, CA). The following PCR primers and a fluorogenic probe were used: sense primer CACACTGCGTCAGCCTACAGA, antisense primer TGTGGTAAAGTGGGACGGAGTT, and probe FAM CTCCCACATGGACCCGCTGGG TAMARA. Taqman PCR for TNF- was performed as
described previously.3 The levels of IL-25 or TNF- mRNA
were normalized to the levels of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA (Applied Biosystems).
Immunoblotting After BMMCs were stimulated with A23187 + PMA at 37°C for 3 hours, culture supernatant was collected by centrifugation, concentrated with Microcon (Millipore, Billerica, MA), and separated on 12% sodium dodecyl sulfate (SDS) gel. Rabbit antisera to murine IL-25 were produced using synthetic peptide (CPSKEQEPPEEW) as an antigen according to the standard protocol.12 The antigenic peptide did not exhibit any significant similarity to other IL-17 family members. Immunoblotting was performed as described previously.13
To determine whether mast cells produce IL-25 upon
activation, we first examined the expression of IL-25 mRNA in BMMCs by RT-PCR analysis. When BMMCs were stimulated with IgE cross-linking by
anti-DNP IgE + DNP-HSA, BMMCs produced IL-25 mRNA at levels comparable with those of activated TH2 cells (Figure
1A). We also obtained similar results
using sorted c-kit-positive BMMCs (data not shown). CFTL-15 cells, a
mast cell line, also expressed IL-25 mRNA upon activation with
A23187 + PMA (Figure 1A). In addition, we confirmed the expression
of IL-25 mRNA by sequencing. By contrast, neither splenic B cells nor a
B-cell line (M12 cells) expressed IL-25 mRNA upon activation
with LPS (Figure 1A). Among various conditions we tested, the best
stimulation for IL-25 mRNA expression in BMMCs was IgE cross-linking
(anti-DNP IgE + DNP-HSA) or A23187 + PMA (Figure 1B). A23187
alone or PMA alone induced IL-25 mRNA expression at lower levels
(Figure 1B). LPS also weakly induced IL-25 mRNA expression (Figure 1B).
On the other hand, neither IL-3 nor SCF induced IL-25 mRNA expression
in BMMCs (Figure 1B). Interestingly, cyclosporin A inhibited IL-25 mRNA
expression induced by IgE cross-linking (Figure 1B). Real-time PCR
analysis revealed that cyclosporin A significantly decreased the IL-25
mRNA expression by 88% (n = 4, P < .01) (Figure 1C).
These results suggest that a calcineurin-dependent pathway is essential
for IL-25 mRNA expression in IgE-stimulated mast cells.
We next examined the kinetics of IL-25 mRNA expression in mast
cells. As shown in Figure 1D, IL-25 mRNA expression reached a peak
within 1 hour after stimulation and decreased to the baseline levels at
3 hours. The peak of IL-25 production was faster than that of TNF- To examine IL-25 production at protein levels, we generated antisera to murine IL-25. The antisera could detect recombinant murine IL-25 but did not react with IL-17 (Figure 1F). When BMMCs were stimulated with A23187 + PMA for 3 hours and culture supernatant was subjected to immunoblotting, a specific band was detected at approximately 17 kDa with antisera to murine IL-25 but not with preimmune serum (Figure 1G). These results suggest that BMMCs release IL-25 protein upon activation. Finally, to determine whether mast cells selectively produce IL-25, we
performed RT-PCR analysis for other IL-17 family cytokines (IL-17,
IL-17B, IL-17C, IL-17D, or IL-17F). Interestingly, in addition to IL-25
mRNA, BMMCs expressed IL-17F mRNA upon IgE cross-linking (Figure
2). In contrast, BMMCs did not express
mRNA for IL-17, IL-17B, IL-17C, or IL-17D (Figure 2 and data not
shown). On the other hand, activated TH2 cells expressed
mRNA not only for IL-25 and IL-17F but also for IL-17 (Figure 2),
suggesting that the expression of IL-17 family cytokines is differently
regulated between mast cells and TH2 cells.
In summary, we show that, upon IgE cross-linking, mast cells produce IL-25. Because IL-25 induces IgE production and eosinophilic inflammation in multiple tissues through the expression of IL-4, IL-5, and IL-13, our findings suggest that mast cell-derived IL-25 may play a pivotal role in IgE-dependent atopic diseases.
We thank Dr K. M. Murphy for DO11.10 mice and Dr M. A. Brown for CFTL-15 cells.
Submitted September 16, 2002; accepted December 24, 2002.
Prepublished online as Blood First Edition Paper, January 2, 2003; DOI 10.1182/blood-2002-09-2817.
Supported in part by grants from the Ministry of Education, Science and Culture, Japan, and Health Science Research Grants, Japan.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Hiroshi Nakajima, Department of Internal Medicine II, Chiba University School of Medicine, 1-8-1 Inohana, Chiba City, Chiba 260-8670, Japan; e-mail: nakajimh{at}intmed02.m.chiba-u.ac.jp.
1.
Aggarwal S, Gurney AL.
IL-17: prototype member of an emerging cytokine family.
J Leukoc Biol.
2002;71:1-8
2.
Hurst SD, Muchamuel T, Gorman DM, et al.
New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25.
J Immunol.
2002;169:443-453
3.
Pan G, French D, Mao W, et al.
Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice.
J Immunol.
2001;167:6559-6567 4. Fort MM, Cheung J, Yen D, et al. IL-25, a novel molecule that induces IL-4, IL-5 and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985-995[Medline] [Order article via Infotrieve].
5.
Schwarzenberger P, La Russa V, Miller A, et al.
IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines.
J Immunol.
1998;161:6383-6389 6. Linden A, Hoshino H, Laan M. Airway neutrophils and interleukin-17. Eur Respir J. 2000;15:973-977[CrossRef][Medline] [Order article via Infotrieve].
7.
Shi Y, Ullrich SJ, Zhang J, et al.
A novel cytokine receptor-ligand pair: identification, molecular characterization, and in vivo immunomodulatory activity.
J Biol Chem.
2000;275:19167-19176
8.
Suzuki K, Nakajima H, Watanabe N, et al.
Role of common cytokine receptor 9. Brown MA, Pierce JH, Watson CJ, Falco J, Ihle JN, Paul WE. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell. 1987;50:809-818[Medline] [Order article via Infotrieve].
10.
Kagami S-i, Nakajima H, Suto A, et al.
Stat5a regulates T helper cell differentiation by several distinct mechanisms.
Blood.
2001;97:2358-2365
11.
Suto A, Nakajima H, Hirose K, et al.
Interleukin-21 prevents antigen-induced IgE production by inhibiting germline C 12. Cooper HM. Production of antibody. In: Coligan JE,Kruisbeek AM,Margulies DH,Shevach EM,Strober W, eds. Current Protocol in Immunology. New York, NY: John Wiley & Sons; 1992:2.4.1-2.4.7.
13.
Suzuki K, Nakajima H, Kagami S-i, et al.
Proteolytic processing of Stat6 signaling in mast cells as a negative-regulatory mechanism.
J Exp Med.
2002;196:27-38
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
J.-S. Jung, B. L. Park, H. S. Cheong, J. S. Bae, J.-H. Kim, H. S. Chang, T. Rhim, J.-S. Park, A.-S. Jang, Y.-M. Lee, et al. Association of IL-17RB Gene Polymorphism With Asthma Chest, May 1, 2009; 135(5): 1173 - 1180. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Caruso, C. Stolfi, M. Sarra, A. Rizzo, M. C. Fantini, F. Pallone, T. T. MacDonald, and G. Monteleone Inhibition of monocyte-derived inflammatory cytokines by IL-25 occurs via p38 Map kinase-dependent induction of Socs-3 Blood, April 9, 2009; 113(15): 3512 - 3519. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-H. Wang, P. Angkasekwinai, N. Lu, K. S. Voo, K. Arima, S. Hanabuchi, A. Hippe, C. J. Corrigan, C. Dong, B. Homey, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC activated Th2 memory cells J. Exp. Med., August 6, 2007; 204(8): 1837 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Kleinschek, A. M. Owyang, B. Joyce-Shaikh, C. L. Langrish, Y. Chen, D. M. Gorman, W. M. Blumenschein, T. McClanahan, F. Brombacher, S. D. Hurst, et al. IL-25 regulates Th17 function in autoimmune inflammation J. Exp. Med., January 22, 2007; 204(1): 161 - 170. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kitawaki, N. Kadowaki, N. Sugimoto, N. Kambe, T. Hori, Y. Miyachi, T. Nakahata, and T. Uchiyama IgE-activated mast cells in combination with pro-inflammatory factors induce Th2-promoting dendritic cells Int. Immunol., December 1, 2006; 18(12): 1789 - 1799. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lajoie-Kadoch, P. Joubert, S. Letuve, A. J. Halayko, J. G. Martin, A. Soussi-Gounni, and Q. Hamid TNF-{alpha} and IFN-{gamma} inversely modulate expression of the IL-17E receptor in airway smooth muscle cells Am J Physiol Lung Cell Mol Physiol, June 1, 2006; 290(6): L1238 - L1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Owyang, C. Zaph, E. H. Wilson, K. J. Guild, T. McClanahan, H. R. P. Miller, D. J. Cua, M. Goldschmidt, C. A. Hunter, R. A. Kastelein, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract J. Exp. Med., April 17, 2006; 203(4): 843 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. G. Fallon, S. J. Ballantyne, N. E. Mangan, J. L. Barlow, A. Dasvarma, D. R. Hewett, A. McIlgorm, H. E. Jolin, and A. N.J. McKenzie Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion J. Exp. Med., April 17, 2006; 203(4): 1105 - 1116. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Maezawa, H. Nakajima, K. Suzuki, T. Tamachi, K. Ikeda, J.-i. Inoue, Y. Saito, and I. Iwamoto Involvement of TNF Receptor-Associated Factor 6 in IL-25 Receptor Signaling J. Immunol., January 15, 2006; 176(2): 1013 - 1018. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-M. Kang, A.-S. Jang, M.-H. Ahn, J.-A. Shin, J.-H. Kim, Y.-S. Choi, T.-Y. Rhim, and C.-S. Park Interleukin-25 and Interleukin-13 Production by Alveolar Macrophages in Response to Particles Am. J. Respir. Cell Mol. Biol., September 1, 2005; 33(3): 290 - 296. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Wong, P. F. Y. Cheung, W. K. Ip, and C. W. K. Lam Interleukin-25-Induced Chemokines and Interleukin-6 Release from Eosinophils Is Mediated by p38 Mitogen-Activated Protein Kinase, c-Jun N-Terminal Kinase, and Nuclear Factor-{kappa}B Am. J. Respir. Cell Mol. Biol., August 1, 2005; 33(2): 186 - 194. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Suzuki, H. Nakajima, K. Ikeda, Y. Maezawa, A. Suto, H. Takatori, Y. Saito, and I. Iwamoto IL-4-Stat6 Signaling Induces Tristetraprolin Expression and Inhibits TNF-{alpha} Production in Mast Cells J. Exp. Med., December 1, 2003; 198(11): 1717 - 1727. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||